April 2016:
New and recently updated articles

August 2013:
L-FABP is introduced as a promising CKD biomarker in the CKD guideline issued by Japanese Society of Nephrology.

December 2012:
RENISCHEM® started distribution in Denmark.
October 2012:
L-FABP ELISA kit manufactured by CMIC were registered as CE marked IVD product in Europe. (The name of the CE marked L-FABP ELISA kit is RENISCHEM®)
March 2012:
KDIGO (Kidney Disease Improving Global Outcomes) selected L-FABP as one of the major 5 biomarkers in the world for detecting AKI (Acute Kidney Injury).
September 2011:
The ADQI (Acute Dialysis Quality Initiatives) members discussed L-FABP as AKI biomarker in Dublin.
August 2011:
The MHLW (Ministry of Health, Labour and Welfare) approved L-FABP ELISA kit produced by CMIC as reimbursed IVD product.
◆Nature Medicine. 19(7):816-817, 2013.
Background in Context for Cardiorenal Diseases: Possibilities of the New Biomarker, L-FABP

◆RENISCHEM® brochure
Please be informed that RENISCHEM® is currently distributed in Denmark for human diagnostic use.
For further information on research use kit, please click here.

Schematic diagram of glomerulus and renal tubule

Conventional markers are excreted in urine due to tissue damage in the glomerulus and renal tubule.

Glomerular damage

Dysfunction of filtration

Albumin (Alb)
Type IV collagen
Disorder of tubular reabsorption


Tubular injury / inflammation

A highly sensitive NEW renal biomarker
L-FABP is a kind of "fatty acid binding proteins" with a molecular weight of 14kDa located in the cytoplasm of human renal proximal tubular cells.
L-FABPs are excreted in urine due to:
  • ischemia (or low capillary blood flow) and
  • oxidative stress on renal tubule
before progression of tissue damage

Useful for early diagnosis of
renal disease accompanying tubular dysfunction
Tubular ischemia

Increase of
oxidative stress